MEtatastic Renal Carcinoma LINes (MERLIN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03928964|
Recruitment Status : Active, not recruiting
First Posted : April 26, 2019
Last Update Posted : April 30, 2019
The hypothesis of this study are as follows:
- Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
- In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
- The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.
|Condition or disease|
|Renal Cell Carcinoma|
|Study Type :||Observational|
|Estimated Enrollment :||440 participants|
|Official Title:||Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data|
|Actual Study Start Date :||January 15, 2018|
|Actual Primary Completion Date :||October 3, 2018|
|Estimated Study Completion Date :||April 2019|
- Overall survival after the first line of treatment [ Time Frame: year 11 ]Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928964
|CHU de Besançon|
|Hôpital Henri Mondor|
|Hôpital Nord Franche-Comté Montbéliard|
|Hôpital Européen Georges Pompidou|
|Institut Mutualiste Montsouris|
|Hôpital d'Instruction des Armées de Bégin|
|Principal Investigator:||Benoit Rousseau, MD||Hôpital Henri Mondor|